Intervention: Pharmacological intervention

This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents

MUCOBOOST

France
|
2025-2028
  • Adults (18-64 years)
  • General population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Levy

France
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Vasilyuk

Russia
|
2024-2024
  • Adults (18-64 years)
  • General population
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Aterixen

Foucher

France
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Influenza virus
  • Influenza-like illness/Acute respiratory infection
  • Pharmacological intervention
  • Antivirals

Ylä-Herttuala

Finland
|
2026-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

Gamaleya

Russia
|
2025-2025
  • Adults (18-64 years)
  • General population
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies

Ziegler

Austria Belgium Germany Sweden United Kingdom
|
2024-2027
  • Infants (<1 year)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination

MOVe-NOW

Argentina Brazil Bulgaria Colombia Finland France Georgia Germany Italy Japan Mexico New Zealand Peru Philippines Poland Puerto Rico Romania Spain Taiwan Thailand Ukraine United Kingdom United States of America
|
2024-2031
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

Pfizer C5091010

Belgium
|
2024-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir

DAN-COVID

Denmark
|
2025-2026
  • Adults (18-64 years)
  • General population
  • Outpatient clinic
  • SARS-CoV-2
  • Pharmacological intervention
  • Vaccination
  • Spikevax

Pfizer C5091018

Argentina Belgium Brazil Denmark France Germany Greece Japan Mexico Netherlands Puerto Rico Slovakia South Korea Spain Sweden Taiwan Türkiye United States of America
|
2025-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Immunocompromised patients
  • Hospital
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Ibuzatrelvir

Pfizer C5091017

Argentina Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany Japan Mexico Slovakia South Africa South Korea Spain Taiwan Türkiye United States of America
|
2024-2028
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Outpatient clinic
  • Primary care
  • SARS-CoV-2
  • Pharmacological intervention
  • Antivirals
  • Ibuzatrelvir